BRAF and hypertensive disorder: More specifically, a BRAF/MEK inhibitor combination therapy resulted in a higher incidence of LVEF reduction (8.1% versus 2% for monotherapy) and hypertension (19.5% versus 14% for monotherapy) than BRAF monotherapy [93].